# China Pharma Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2020

- Company: [China Pharma Holdings, Inc.](/companies/cphi.md) (CIK 1106644)
- Form: 10-Q
- Filed: 2020-05-14
- Accepted by EDGAR: May 14, 2020, 16:07 ET
- Period: 2020-03-31
- Accession: 0001213900-20-012258
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1106644/000121390020012258/f10q0320_chinapharmaholdings.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1106644/000121390020012258/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-01-01 to 2020-03-31 | $1.8m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-01-01 to 2020-03-31 | $1.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2020-01-01 to 2020-03-31 | $194.4k | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $48.8k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | −$599.3k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-01-01 to 2020-03-31 | $62.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | −$660.9k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | −$244.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-01-01 to 2020-03-31 | $347.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-03-31 | $145.9k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $6.4m | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $22.4m | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $11.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $14.1m | us-gaap:Liabilities |
| Long-term debt | at 2020-03-31 | $4.1m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2020-03-31 | $8.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 26,487 characters.

The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as “anticipate,” “believe,” “expect,” “plan,” “intend,” “seek,” “estimate,” “project,” “could,” or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the readers that any such forward-looking statements contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report and some of which are discussed in our other filings with the Securities and Exchange Commission (the “SEC”). These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.

These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward-looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

### Business Overview & Recent Developments

We are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People’s Republic of China (the “PRC”). All of our operations are conducted in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, CFDA based upon demonstrated safety and efficacy.

China’s consistency evaluation of generic drugs had continued to proceed in 2019. The supporting policies from central and provincial governments have been constantly issued. We have always taken the tasks of facilitating the consistency evaluation as our top priority, and worked on them actively. However, due to the continuous dynamic changes of the detailed policies, future market, expected investment, and return of investment (“ROI”) for each drug’s consistency evaluation, the whole industry, including us, has been making slow progresses in terms of the consistency evaluation.

On one hand, since initiated in 2018, two rounds of “4 + 7” (refers to 11 selected pilot cities, including 4 municipalities and 7 other cities) Group Purchasing Organization (“GPO”) activities have been carried out by the end of 2019, which significantly reduced the price of the drugs that won the bids. On the other hand, the consistency evaluation has been adopted as one of the qualification standards for participating in the GPO activities. In this context, we have to take a more cautious and flexible attitude towards the initiating and progressing any project for an existing product’s consistency evaluation and to cope with the changing macro environment of drug sales in China.

In addition, we continue to explore in the field of comprehensive healthcare. Comprehensive healthcare is a general concept proposed according to the development of the times, social needs and changes in disease spectrum. It focuses on people’s daily life, aging and disease, pays attention to all kinds of risk factors and misunderstandings affecting health, and calls for self-health management, and advocates the comprehensive care of the entire process of life. It covers all kinds of health-related information, products and services, as well as actions taken by various organizations to meet the health needs. We launched Noni enzyme, a natural, healthy and nutrition-rich food supplement at the end of 2018, and wash-free sanitizer and mask in early 2020 to address the market needs caused by COVID-19 in China.

We will continue to optimize our product structure and actively respond to the current health needs of human beings.

### Market Trends

According to the data of the Chinese National Bureau of Statistics, from January to November 2019, the number of Chinese pharmaceutical manufacturing enterprises was 7,346; the operating revenue was RMB2159.65 billion (approximately USD313 billion), which represented an increase of 8.9% from the same period last year. As the medical reform deepens, the GPO has been expanded from pilot cities to the whole country, which pressed hospitals to control drug prices to reduce overall costs. The pressure of price reduction has been further transmitted to pharmaceutical manufacturers. We believe that the price control is still one of the key themes in the pharmaceutical industry in the future; and pharmaceutical manufacturing companies’ revenue is under obvious pressure.

Novel coronavirus pneumonia (COVID-19) refers to the pneumonia caused by the 2019 novel coronavirus infection. The World Health Organization (WHO) declared the COVID-19 outbreak a “public health emergency of international concern” (PHEIC) on January 30, 2020. According to the Chinese National Health Commission of the People’s Republic of China, the cumulative number of confirmed cases of COVID-19 infection had reached 82,919 in China; and according to the major medias, the confirmed cases had reached 4,186,260 in the rest of the world by May 11, 2020.

We believe that several new development opportunities are emerged in China’s healthcare sector in connection with this outbreak due to the following reasons: there is a gap between prevention and treatment of diseases; the level of treatment skills and conditions of primary medical institutions needs to be improved; large hospitals are overcrowded; and there are too many restrictions on the internet healthcare service. The impact of the pandemic will bring more governmental and social attention to China’s health care industry, which we believe will promote its overall development, and trigger potential adjustments in products and service, and sales channel in the health care industry.

As a generic drug company we are presented with a huge domestic market. We believe that through further upgrades and consistency evaluations, we will be able to meet the European and American production standards, which enables us to export our products to overseas markets. In the future, cost management and control ability will gradually become an important factor in determining the competitiveness of generic pharmaceutical enterprises. Although price control leads to a decline in the profitability, the GPO’s winning enterprise has a good chance of achieving price-for-volume in order to increase its market share and support its continuous innovation transformation. In addition, consumption upgrading in China drives the increase of optional consumption. With the improvement of residents’ quality of life, the healthcare demand is also changing. We believe that there are a large number of unmet demands in comprehensive healthcare and Internet healthcare sectors.

In addition, the Office of the State Council issued “*Pilot Plan for Marketing Authorization Holders”* on May 24, 2016, allowing eligible drug research and development institutions and scientific researchers to become Marketing Authorization Holders (“MAH”) by obtaining drug marketing authorization and drug approval numbers from the State Council. This policy uses a management model of separating drug marketing authorization and drug production licenses, thereby allowing an MAH to produce pharmaceuticals itself or to consign production to other pharmaceutical manufacturers. This policy not only transitions our production practices to meet the European and United States standards by separating drug approval and production qualifications, and therefore changing the existing model of bundling drug approval numbers to pharmaceutical manufacturers in China, but also serves as a supplement to the ongoing consistency evaluations policy.

The Drug Administration Law of the People’s Republic of China (hereinafter referred to as the Drug Administration Law) was amended and adopted by the 12th session of the Standing Committee of the 13th National People’s Congress of the People’s Republic of China on August 26, 2019, and came into effect on December 1, 2019. Chapter III of the Drug Administration Act contains the interpretation and regulation of MAH. This marks that MAH has been officially introduced as a national system after four years of pilot work. We believe this will have a profound impact on the future pharmaceutical industry and drug management. Furthermore the promotion of this policy presents us the opportunity to use our professional pharmaceutical production facilities in Haikou, Hainan, China, to carry out the contract manufacture.

In general, demand for pharmaceutical products is still experiencing steady growth in China. We believe the ongoing generic drug consistency evaluations and reform of China’s drug production registration and review policies will have major effects on the future development of our industry and may change its business patterns. We will continue to actively adapt to the national policy guidance and further evaluate market conditions for our existing products, and competition in the market in order to optimize our development strategy.

### Results of Operations for the three months ended March 31, 2020

### Revenue

Revenue decreased by 39.8% to $1.8 million for the three months ended March 31, 2020, as compared to $2.9 million for the three months ended March 31, 2019. This decrease was mainly due to the negative impact of the outbreak of COVID-19. Since the Chinese New Year holiday in early February, almost all Chinese companies, including us, have delayed the resumption of work. And our work resumption gradually returned to 90% by the end of March 2020.

Set forth below are our revenues by product category in millions (USD) for the three months ended March 31, 2020 and 2019:

| Product Category | Three Months Ended March 31, 2020 | 2019 | Net Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| CNS Cerebral & Cardio Vascular | 0.25 | 0.46 | -0.21 | -46% |
| Anti-Viral/ Infection & Respiratory | 1.20 | 1.85 | -0.66 | -35% |
| Digestive Diseases | 0.06 | 0.12 | -0.05 | -45% |
| Other | 0.25 | 0.50 | -0.25 | -49% |

The most significant revenue decrease in terms of dollar amount was in our “Anti-Viral/Infection & Respiratory” product category, which generated $1.20 million in sales revenue in the three months ended March 31, 2020 compared to $1.85 million for the same period a year ago, which is a decrease of $0.66 million. This decrease was mainly due to the decrease in sales of Cefaclor, which was caused by market volatility.

Our “Other” product category sales decreased by $0.25 million to $0.25 million in the three months ended March 31, 2020 from $0.50 million for the same period in 2019, which was mainly due to the decrease in sales of Vitamin B6 that was caused by market volatility.

Sales in the “CNS Cerebral & Cardio Vascular” product category decreased to $0.25 million in the three months ended March 31, 2020, as compared to $0.46 million for the same period in 2019. Our “Digestive Diseases” product category generated $0.06 million and $0.12 million of sales in the three months ended March 31, 2020 and 2019, respectively.

| Product Category | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| CNS Cerebral & Cardio Vascular | 14% | 16% |
| Anti-Viral/ Infection & Respiratory | 68% | 63% |
| Digestive Diseases | 4% | 4% |
| Other | 14% | 17% |

For the three months ended March 31, 2020, revenue breakdown by product category remained similar to that of the same period in 2019. Sales of the “Anti-Viral/Infection & Respiratory” products category represented 68% and 63% of total sales in the three months ended March 31, 2020 and 2019, respectively. The “CNS Cerebral & Cardio Vascular” product category represented 14% and 16% of total revenue in the three months ended March 31, 2020 and 2019, respectively. The “Other” product category represented 14% and 17% of revenues in the three months ended March 31, 2020 and 2019, respectively. The “Digestive Diseases” product category represented both 4% of total revenue in the three months ended March 31, 2020 and 2019, respectively.

### Cost of Revenue

For the three months ended March 31, 2020, our cost of revenue was $1.6 million, or 89% of total revenue, while cost of revenue was $2.3 million, or 78% of total revenue, for the same period in 2019.

### Gross Profit and Gross Margin

Gross profit for the three months ended March 31, 2020 was $0.2 million, as compared to $0.7 million during the same period in 2019. Our gross profit margin in the three months ended March 31, 2020 was 11.0% as compared to 22.4% during the same period in 2019. The decrease in our gross profit margin was mainly due to the decrease in revenue and the increased ratio of fixed cost to revenue.

### Selling Expenses

Our selling expenses for the three months ended March 31, 2020 and 2019 were $0.3 million and $0.5 million, respectively. Selling expenses accounted for 18.5% of the total revenue in the three months ended March 31, 2020, as compared to 16.3% during the same period in 2019. As a result of the adjustment of many policies of healthcare reform, we had reduced number of personnel and expenses to efficiently support our sales and the collection of accounts receivable.

### General and Administrative Expenses

Our general and administrative expenses were both $0.4 million for the three months ended March 31, 2020 and 2019, respectively. It accounted for 22.0% and 14.6% of our total revenues in the three months ended March 31, 2020 and 2019, respectively.

### Research and Development Expenses

Our research and development expenses for the three months ended March 31, 2020 were $0.05 million, as compared to $0.07 million in the same period in 2019. Research and development expenses accounted for 2.8% and 2.4% of our total revenues in the three months ended March 31, 2020 and 2019, respectively. These expenditures were mainly for the consistency evaluations of our existing products.

### Bad Debt Expenses

Our bad debt expenses for the three months ended March 31, 2020 were $30,246, as compared to $13,312 for the same period in 2019. The increase in our bad debt expenses in this period was partially due to the slowed down collection of bad debt because of the national wide delayed work resumption caused by COVID-19.

We increased our customer credit or payment terms from 90 days to 180 days in the fourth quarter of 2018 in order to better reflect our actual operating environment. Due to the peculiar circumstances affecting the Chinese pharmaceutical market, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon. Our customers are primarily pharmaceutical distributors that sell our products to mostly government-backed hospitals. Therefore, the aging of our receivables from our customers tends to be longer-term.

The amount of accounts receivable that was past due (or the amount of accounts receivable that were more than 180 days old) was $0.13 million and $0.15 million as of March 31, 2020 and December 31, 2019, respectively.

The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of March 31, 2020 and December 31, 2019:

|  | March 31, 2020 | December 31, 2019 |
| --- | ---: | ---: |
| 1 - 180 Days | 4.02% | 3.14% |
| 180 - 360 Days | 0.60% | 0.69% |
| 360 - 720 Days | 0.50% | 0.59% |
| \> 720 Days | 94.88% | 95.58% |
| Total | 100.00% | 100.00% |

In the fourth quarter of 2018, our bad debt allowance estimate has been updated to a policy which requires no allowance of accounts receivable recognized that are within 180 days old, 10% of accounts receivable that are between 180 days and 365 days old, 70% of accounts receivable that are between 365 days and 720 days old, and 100% of accounts receivable that are greater than 720 days old. Prior to that, our policy was no allowance of accounts receivable recognized that are within 90 days old, 10% of accounts receivable that are between 90 days and 365 days old, 70% of accounts receivable that are between 365 days and 720 days old, and 100% of accounts receivable that are greater than 720 days old.

We recognize bad debt expenses per actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and, when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. We also consider and assess the recoverability of individual account receivable balances. The allowance for doubtful accounts was $17.3 million and $17.6 million as of March 31, 2020 and December 31, 2019, respectively. The changes in the allowances for doubtful accounts during the three months ended March 31, 2020 and 2019 were as follows:

|  | For the Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Balance, Beginning of Period | $17,575,100 | $17,815,075 |
| Bad debt expense (benefit) | 30,246 | 13,312 |
| Foreign currency translation adjustment | -270,527 | 467,505 |
| Balance, End of Period | $17,334,819 | $18,295,892 |

### Loss from Operations

Our operating loss for the three months ended March 31, 2020 was $0.6 million, compared to an operating loss of $0.3 million during the same period in 2019.

### Net Interest Expense

Net interest expense for the three months ended March 31, 2020 was $0.06 million, as compared to $0.08 million for the same period in 2019.

### Net Loss

Net Loss for the three months ended March 31, 2020 was $0.7 million, as compared to a net loss of $0.4 million for the same period a year ago. The increase in net loss was mainly the result of decreased revenue, whereas the expenditures did not decrease in proportion to revenue, which was due to fixed costs.

Loss per basic and diluted common share were $0.02 for the three months ended March 31, 2020, and $0.01 for the same period in 2019.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 43,579,557 for both the three months ended March 31, 2020 and 2019.

### Liquidity and Capital Resources

Our principal source of liquidity is cash generated from operations. Our cash and cash equivalents were $0.1 million, representing 0.7% of our total assets, as of March 31, 2020, as compared to $1.1 million, representing 4.8% of our total assets as of December 31, 2019. All of the $0.1 million of cash and cash equivalents as of March 31, 2020, are considered to be reinvested indefinitely in the Company’s Chinese subsidiary, Helpson and is not expected to be available for payment of dividends or for other payments to its parent company or to its shareholders. We entered into an eight-year construction loan facility on September 21, 2013. The total loan facility amount is RMB 80 million (approximately $11.7 million), which had been fully utilized through May 7, 2014. As of March 31, 2020, we have accumulatively repaid the principal of RMB 51 million (approximately $7.3 million) of the construction loans, per the loan repayment schedule. The total balance of the construction loan facility is $4.1 million as of March 31, 2020, which includes $1.98 million current portion, and $2.12 non-current portion. Cash flow generated from operating activities was used to fund our daily operating expenses as well as the repayment of our loan facility.

As discussed in Note 14, in April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) have been advanced. The loan bears interest at a rate of 4.25% per annum. The Company has an additional RMB 5,000,000 (approximately $0.7 million) available under the line, subject to a risk review and approval by a third party guarantee company.

Based on our current operating plan, management believes that cash provided by operations, in addition to the newly obtained line of credit in April 2020 will be sufficient to meet our working capital needs and our anticipated capital expenditures, including expenditures for new formula acquisitions for the next twelve months. However, if circumstances change and we do not follow our operating plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, we may seek additional debt or equity financing as necessary for expansion purposes and when we believe the market conditions are the most advantageous to us. Although our Chairperson and Chief Executive Officer had advanced funds for working capital during 2019 and the first quarter of 2020, there can be no assurances that this will be the case in the future. There can be no assurance that any additional financing will be available on acceptable terms, if at all.

### Operating Activities

Net cash consumed by operating activities was both $0.2 million in the three months ended March 31, 2020 and 2019, respectively.

As of March 31, 2020, our net accounts receivable were $0.9 million, as compared to $0.6 million, as of December 31, 2019.

Total inventory was both $3.6 million, as of March 31, 2019 and December 31, 2019.

### Investing Activities

During the three months ended March 31, 2020, net cash used in investing activities was $0.35 million as compared to $0.07 million for the three months ended March 31, 2019.

### Financing Activities

Cash flow used in financing activities was $0.1 million in the three months ended March 31, 2020, as compared to $0.3 million in the three months ended March 31, 2019. The decrease in cash flow used in financing activities was mainly due to the repayment of the RMB 15 million (approximately $2.3 million) line of loan facility in 2019.

According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies’ registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. As of March 31, 2020 and December 31, 2019, Helpson’s net assets totaled $6,510,000 and $7,189,000, respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson’s net assets that was designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, was 50% of Helpson’s registered capital, which is $8,145,000 as of March 31, 2020 and December 31, 2019, respectively. There were no allocations to the statutory surplus reserve accounts during the three months ended March 31, 2020.

The Chinese government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of China. Our businesses and assets are primarily denominated in RMB. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires the submission of a payment application form together with certain invoices and executed contracts. The currency exchange control procedures imposed by Chinese government authorities may restrict the ability of Helpson, our Chinese subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.

### Off-Balance Sheet Arrangements

As of March 31, 2020, we did not have any off-balance sheet arrangements.

### Critical Accounting Policies

Management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Our financial statements reflect the selection and application of accounting policies that require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, “Organization and Significant Accounting Policies”, is incorporated herein by reference.

## Market risk

As filed, 139 characters.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

## Controls and procedures

As filed, 2,555 characters.

### Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2020 to satisfy the objectives for which they are intended. This was due to the material weakness in our internal control over financial reporting, with respect to our lack of accounting financial reporting personnel who were knowledgeable in U.S. GAAP, as disclosed in our annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 30, 2020. Notwithstanding the aforementioned material weakness, management has concluded that our consolidated financial statements included in this report are fairly stated in all material respects in accordance with U.S. GAAP for each period presented herein.

### Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 14, 2020.
Source: SEC EDGAR, the filing index for accession 0001213900-20-012258. Last ingested by Listed: Nov 11, 2026, 00:23 ET. No prices; not investment advice.
